Method and apparatus for accurate parametric mapping
10895621 ยท 2021-01-19
Assignee
Inventors
- Kyung Sung (Los Angeles, CA, US)
- Holden Wu (Los Angeles, CA, US)
- Novena Rangwala (Los Angeles, CA, US)
Cpc classification
G01R33/5608
PHYSICS
G01R33/50
PHYSICS
G06T2207/10096
PHYSICS
International classification
G01R33/56
PHYSICS
G06T3/40
PHYSICS
G01R33/50
PHYSICS
Abstract
Systems and methods are disclosed for a simultaneous 3D T.sub.1 and B.sub.1.sup.+ mapping technique based on VFA imaging using a reference region VFA (RR-VFA) approach to eliminate the need for a separate B.sub.1.sup.+ mapping scan while imaging the prostate. The RR-VFA method assumes the existence of a reference region that is distributed throughout the volume of interest and is well characterized by a known T.sub.1 relaxation time. In particular, fat is generally selected as the reference region due to its distribution in the body. B.sub.1.sup.+ inhomogeneity is estimated in the fat tissue and interpolated over the entire volume of interest, thus eliminating the need for an additional scan.
Claims
1. An apparatus for parametric imaging of a target tissue, comprising: (a) a processor configured for receiving MRI scan data from an MRI scanner configured for generating scans on a specific anatomical location, and reference tissue region data; and (b) a non-transitory memory storing instructions executable by the processor; (c) wherein said instructions, when executed by the processor, perform steps for parametric mapping of the target tissue comprising: (i) acquiring MRI scans having one or more images of the target tissue and surrounding target tissues by performing quantitative dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) at 3T using three-dimensional RF-spoiled gradient echo images with variable flip angles (VFA) to generate the parametric map comprising T.sub.1 measurements, wherein said target tissue comprises a tissue, having an unknown or variable imaging characteristic or parameter; (ii) receiving characteristics of an internally or externally added reference tissue region comprising a fat tissue in proximity to or at least partially surrounding the target tissue; (iii) identifying and characterizing the reference tissue region within the one or more acquired images, the reference tissue region being adjacent or in proximity to the target tissue within a field of view of the one or more images, the reference tissue region having a known and consistent characteristic parameter within the one or more images and having a consistent characteristic parameter that is known or readily estimated; (iv) utilizing the reference region with its consistent characteristic parameter within a recognized model to generate a tissue mask from which an unknown tissue parameter is estimated for the target tissue; (v) interpolating the estimated unknown tissue parameter of the reference region over the entire field of view of the one or more images; and (vi) outputting image data of the one or more images, the image data comprising a parametric map of the target tissue.
2. The apparatus of claim 1, wherein the target tissue comprises a prostate tissue which is typically devoid of fat tissue.
3. The apparatus of claim 1: wherein T.sub.1 measurements are susceptible to B.sub.1.sup.+ field inhomogeneity comprising errors due to spatial variations in flip angle caused by transmit radiofrequency (RF) from the quantitative DCE-MRI; and wherein outputting image data comprises simultaneously mapping T.sub.1 and B.sub.1.sup.+ field inhomogeneity values associated with the target tissue.
4. The apparatus of claim 3: wherein calculating the unknown parameter in the reference region comprises estimating B.sub.1.sup.+ field inhomogeneity in the fat tissue; and wherein interpolating the calculated unknown parameter of the reference region comprises interpolating the estimating B.sub.1.sup.+ inhomogeneity over at least a portion of the FOV of the one or more images, the portion comprising the target tissue.
5. The apparatus of claim 1: wherein the consistent characteristic parameter comprises an effective fat T.sub.1 value associated with the reference region; and wherein the unknown parameter of the reference region comprises an rFA value associated with the reference region.
6. The apparatus of claim 5, wherein identifying and characterizing a reference tissue region comprises: applying a combination of a user-selectable parameter for fat signal segmentation and a signal fat-fraction threshold; and building a binary fat tissue mask of the reference tissue region.
7. The apparatus of claim 6, wherein Dixon-separated fat and water images are used to build the binary fat mask.
8. The apparatus of claim 6: wherein the binary fat mask is used to characterize an rFA value associated with the reference region; and wherein interpolating the calculated unknown parameter of the reference region comprises interpolating the rFA value at least a portion of the FOV of the one or more images, the portion comprising the target tissue.
9. The apparatus of claim 8, wherein the rFA value comprises B.sub.1.sup.+ field inhomogeneity.
10. The apparatus of claim 6, wherein interpolating the calculated unknown parameter of the reference region comprises computing a fractional volume of outliers comprising a combination of user-selectable parameter for fat signal segmentation, the signal fat-fraction threshold, and effective fat T.sub.1 values.
11. A method for parametric imaging of a target tissue, comprising: (a) acquiring MRI scans having one or more images of the target tissue and surrounding target tissues by performing quantitative dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) at 3T using three-dimensional RF-spoiled gradient echo images with variable flip angles (VFA) to generate the parametric map comprising T.sub.1 measurements, wherein said target tissue comprises a tissue, having an unknown or variable characteristic parameter; (b) receiving characteristics of an internally or externally added reference tissue region comprising a fat tissue in proximity to or at least partially surrounding the target tissue; (c) identifying and characterizing the reference tissue region within the one or more acquired images, the reference tissue region being adjacent or in proximity to the target tissue within a field of view of the one or more images, the reference tissue region having a known and consistent characteristic parameter within the one or more images and having a consistent characteristic parameter that is known or readily estimated; (d) utilizing the reference region with its consistent characteristic parameter within a recognized model to generate a tissue mask from which an unknown tissue parameter is estimated for the target tissue; (e) interpolating the estimated unknown tissue parameter of the reference region over the entire field of view of the one or more images; and (f) outputting image data of the one or more images, the image data comprising a parametric map of the target tissue; (g) wherein said method is performed by a processor, configured for receiving MRI scan data from an MRI scanner configured for generating scans on a specific anatomical location, and reference tissue region data, for executing instructions stored on a non-transitory medium.
12. The method of claim 11, wherein the target tissue comprises a prostate tissue which is typically devoid of fat tissue.
13. The method of claim 11: wherein T.sub.1 measurements are susceptible to B.sub.1.sup.+ field inhomogeneity comprising errors due to spatial variations in flip angle caused by transmit radiofrequency (RF) from the quantitative DCE-MRI; and wherein outputting image data comprises simultaneously mapping T.sub.1 and B.sub.1.sup.+ field inhomogeneity values associated with the target tissue.
14. The method of claim 13: wherein calculating the unknown parameter in the reference region comprises estimating B.sub.1.sup.+ field inhomogeneity in the fat tissue; and wherein interpolating the calculated unknown parameter of the reference region comprises interpolating the estimating B.sub.1.sup.+ inhomogeneity over at least a portion of the FOV of the one or more images, the portion comprising the target tissue.
15. The method of claim 11: wherein the consistent characteristic parameter comprises an effective fat T.sub.1 value associated with the reference region; and wherein the unknown parameter of the reference region comprises an rFA value associated with the reference region.
16. The method of claim 15, wherein identifying and characterizing a reference tissue region comprises: applying a combination of a user-selectable parameter for fat signal segmentation and a signal fat-fraction threshold; and building a binary fat tissue mask of the reference tissue region.
17. The method of claim 16, wherein Dixon-separated fat and water images are used to build the binary fat mask.
18. The method of claim 16: wherein the binary fat mask is used to characterize an rFA value associated with the reference region; and wherein interpolating the calculated unknown parameter of the reference region comprises interpolating the rFA value at least a portion of the FOV of the one or more images, the portion comprising the target tissue.
19. The method of claim 18, wherein the rFA value comprises B.sub.1.sup.+ field inhomogeneity.
20. The method of claim 16, wherein interpolating the calculated unknown parameter of the reference region comprises computing a fractional volume of outliers comprising a combination of user-selectable parameter for fat signal segmentation, the signal fat-fraction threshold and effective fat T.sub.1 values.
Description
BRIEF DESCRIPTION OF THE SEVERAL VIEWS OF THE DRAWING(S)
(1) The technology described herein will be more fully understood by reference to the following drawings which are for illustrative purposes only:
(2)
(3)
(4)
(5)
(6)
(7)
(8)
(9)
(10)
(11)
(12)
(13)
(14)
(15)
(16)
(17)
(18)
(19)
DETAILED DESCRIPTION
(20) I. System Overview
(21)
(22) One specific implementation of method 10 is for imaging the prostate of a patient, and specifically calculation of pixel-based B.sub.1.sup.+ inhomogeneity maps in prostate MRI. Referring to
(23) In this implementation, fat is chosen as a reference tissue region, since it has a uniform and well-defined characteristic T1 relaxation time measurable using MRI. The MRI signal in fat tissue surrounding the prostate can be expressed as a function of imaging parameters: effective fat T.sub.1, and a B.sub.1.sup.+ inhomogeneity-related parameter called relative flip angle (rFA). However, the accuracy of rFA calculated from the equation depends on effective selection of the reference region, i.e., (a) accurate selection of fat tissue using two parameters developed specifically for this purpose, fat signal segmentation factor (i.e. fractional segmentation constant), t.sub.F, and signal fat fraction threshold, r.sub.F, and (b) effective fat T.sub.1, (i.e. T.sub.1f). To choose the most effective values for these parameters in the prostate, a difference metric was developed to compare the rFA map obtained using a combination of r.sub.F, t.sub.F, and T.sub.1f with another rFA map that was acquired as a reference using a protocol available on all scanners from this manufacturer (manufacturer-provided protocol). Further, an error metric was developed using the manufacturer-provided protocol to assess the interpolation accuracy within the prostate.
(24) In one embodiment, the B.sub.1.sup.+ maps are calculated using a standard clinical VFA imaging protocol, acquired using a spoiled gradient-echo (SPGR) sequence with two echo times, followed by Dixon separation of fat and water signal, denoted as S.sub.F and S.sub.W. A position-dependent measure of the B.sub.1.sup.+ inhomogeneity, A(), is defined, and expressed in a percentage unit as relative flip angle (ratio of actual flip angle to prescribed flip angle). A ratio of steady-state SPGR signal magnitude for two prescribed flip angles, .sub.1 and .sub.2, can be expressed as:
(25)
where TR is the repetition time, and is a position vector denoting the pixel coordinates. A(
) can be numerically computed using a theoretical value of the signal ratio as a function of A(
), with knowledge of fat T.sub.1, T.sub.1f, and A(
) can then be spatially interpolated across the tissue of interest, including the prostate.
(26) Referring to
(27) Accurate quantification of rFA using RR-VFA is a function of the selectivity and sparsity of the fat tissue, as it affects not only rFA calculation surrounding the prostate but also spatial interpolation accuracy within the prostate. For example, a highly fat-specific mask (i.e., high selectivity and sparsity) includes pixels with contributions from fat only, resulting in the accurate estimation of rFA, but can reduce the spatial interpolation accuracy within the prostate. On the contrary, a less fat-specific mask (i.e., low selectivity and sparsity) may include pixels with contributions from both fat and water, affecting the calculation of rFA, but can minimize the interpolation errors within the prostate. The following sub-sections will explain our optimization of RR-VFA B.sub.1.sup.+ mapping in the prostate by evaluating the appropriate identification and characterization of fat tissue around the prostate, and the spatial interpolation accuracy within the prostate.
(28) A. Identification and Characterization of Fat Region
(29) To accurately select and characterize fat tissue surrounding the prostate (step 20,
(30)
(31)
where
(32)
denote the Dixon-separated fat and water images for the highest (N.sup.th) flip angle within
(33)
to
(34)
images 32 and
(35)
to
(36)
images 34, respectively. Increasing t.sub.F and r.sub.F reduces errors at the fat-water boundaries and low fat-signal regions, thus improving accuracy, but also increases spatial interpolation errors within the prostate.
(37) Once mask M (36) is determined, rFA (38) may be characterized within the fat tissue, and A.sub.FAT (40), can be calculated (see calculation of unknown parameter step 22 in
(38)
where T.sub.1f is an effective fat T1 value that is assumed to be well characterized prior to RR-VFA. In the presence of B.sub.0 field inhomogeneity, partial volume effects at fat-water boundaries and other system imperfections, T.sub.1f values may be measured differently by various T1 mapping sequences. A population-based effective T.sub.1f was optimized by investigating various T.sub.1f data in the range of 290 ms to 360 ms.
(39) Referring to interpolation step 16 (
(40)
(41) A fractional volume of outliers, , is computed by the number of outliers normalized by the number of fat pixels in a central volume (Vc) and was recorded as a function of t.sub.F (0.3-0.6), r.sub.F (50-98%), and T.sub.1f (290 ms-360 ms) for ten volunteers.
(42)
(43) II. Experiment/Evaluation
(44) A. Evaluation of Interpolation Accuracy
(45) The prostate typically contains no fat, and accurate interpolation is necessary to ensure accurate B.sub.1.sup.+ mapping using RR-VFA in the prostate. Since B.sub.1.sup.+ inhomogeneity varies smoothly over the volume at 3T, three-dimensional linear interpolation (step 16,
(46) The interpolation error, , was defined as the mean of the absolute difference between pre- and post-interpolated rFA within prostate, as follows:
(47)
where M.sub.pros is the volumetric prostate region of interest (ROI) comprising the entire prostate, and N.sub.pros is M the number of pixels within M.sub.pros. The interpolation error was calculated over ten volunteers and expressed using the previously defined range of t.sub.F (0.3-0.6) and r.sub.F (50-98%).
(48) B. Experimental Configuration
(49) All experiments were performed on three Siemens 3T scanners (Skyra (Scanner 1), Trio (Scanner 2), and Prisma (Scanner 3), Erlangen, Germany), using the body coil for RF transmission and receive-only phased-array coil for signal reception. RF transmission modes differed between scanners: Scanners 1 and 3 were operated with TrueForm RF transmission and Scanner 2 was operated with circular polarization. All experiments were performed with the volunteers positioned supine and feet first. Our study was approved by the local institutional review board, and informed written consent was obtained from all volunteers prior to the scans.
(50) For single-scanner evaluation, ten healthy male volunteers (303.6 years, 739 kgs) were scanned on Scanner 1. Images were acquired using the standard clinical VFA imaging protocol at our institution, where the VFA images were acquired using three-dimensional FLASH acquisition with a dual-echo bipolar readout followed by Dixon separation of S.sub.F and S.sub.W. The 3T VFA protocol with Dixon separation does not increase scan time and is available commercially on most 3T MRI scanners. The two echo times were TE.sub.1/TE.sub.2=1.23/2.46 ms to acquire opposed-phase and in-phase images, respectively, and fat- and water-only images were calculated at the scanner using a method based on the two-point Dixon fat-water separation algorithm. This FLASH sequence was repeated with the following four flip angles (FA): 2, 5, 10, and 15. Other imaging parameters common to all protocols were: TR=4.17 ms, FOV=26 cm, partition thickness/spacing=3.6/0.7 mm, 20 partitions, acquisition matrix=160160, averages=3/2/2/2 and scan duration=52/35/35/35 s for FA=2/5/10/15 respectively, for each acquisition.
(51) Reference B.sub.1.sup.+ maps (A.sub.REF) were acquired for comparison using the ratio of images obtained from a combination of spin and stimulated echo excitation. This B.sub.1.sup.+ mapping sequence was the only available option on all three scanners as manufacturer's service B.sub.1.sup.+ measurement and was implemented as a two-dimensional multi-slice acquisition with echo-planar imaging readout for improved time-efficiency (27,28). The other imaging parameters were TR=500 ms, TE=14 ms, FOV=26 cm, slice thickness/spacing=8/16 mm, 7 slices, acquisition matrix=128, scan duration 40 s.
(52) For multi-scanner evaluation, a subset of four volunteers from the Scanner 1 cohort (293.1 years, 74.510.4 kgs) was also scanned on Scanners 2 and 3 using the same VFA protocol mentioned above to compare B.sub.1.sup.+ and T.sub.1 maps across scanners.
(53) C. Data Analysis
(54) RR-VFA was implemented in MATLAB (The Mathworks, Natick, Mass., USA), where rFA maps were calculated from the VFA images using t.sub.F of 0.5, r.sub.F of 90%, and T.sub.1f of 320 ms from the results of the analysis. The rFA maps obtained in the pixels representing fat tissue were smoothed across the imaging volume using a 555 boxcar function prior to interpolation. T.sub.1 maps were generated from the VFA images before and after applying RR-VFA B.sub.1.sup.+ correction. RR-VFA was implemented using all four flip angles by calculating rFA using two sets of two FAs each (2, 10 and 5, 15) in M and calculating rFA as the mean of the two values.
(55) Three ROIs were chosen for analysis, including the volumetric prostate ROI and two ROIs manually selected in the obturator internus muscles left and right of the prostate. These latter muscle ROIs were chosen to check the consistency by comparing rFA and T.sub.1 values on contra lateral sides. Mean and standard deviations were calculated within the ROIs, and T.sub.1 values over 4000 ms were excluded in the calculation to avoid bias due to outliers. For the corrected T.sub.1 maps, the corresponding pixels in the rFA maps were also excluded from calculations. Typically, over 99.5% of the total sample size of the volumetric ROI of the prostate was retained after this step. No pixels in the muscle ROIs were excluded. Statistical f-tests were performed (level of significance set top <0.05) on the mean values to compare T.sub.1 values in the prostate and muscle ROIs before and after applying B.sub.1.sup.+ correction.
(56) III. Experimental Results
(57) A. RR-VFA Optimization in the Prostate
(58) A fractional volume of outliers, , was computed (according to the steps detailed in
(59)
(60) The evaluation of the interpolation accuracy (interpolation error metric, ) is shown in
(61)
(62) B. RR-VFA Evaluation: Single-Scanner
(63)
(64)
(65) In
(66) C. RR-VFA Evaluation: Multi-Scanner
(67)
(68) Table 2A and Table 2B show a summary of the results of RR-VFA applied in four healthy volunteers on three different MRI scanners. The first four lines show mean A.sub.RR-VFA in the prostate ROI per volunteer and per scanner, and T.sub.1non and the resulting T.sub.1RR-VFA. The bottom line shows the mean prostate A.sub.RR-VFA in the group of four volunteers. Table 2A and Table 2B demonstrate reduced range of T.sub.1RR-VFA compared with T.sub.1non, within each scanner and across scanners, with a large range of T.sub.1non values for different volunteers and scanners (1760278 ms, range: 1260 ms to 2119 ms) and with a lower range of T.sub.1RR-VFA (1921131 ms, range: 1646-2072 ms). The individual volunteers show that CoV in T.sub.1non reduced from 6-28% to 1-12% in T.sub.1RR-VFA.
(69) III. System Hardware Configuration
(70)
(71) IV. Discussion/Conclusions
(72) An objective of the present description is an optimized RR-VFA method to simultaneously map T.sub.1 and B.sub.1.sup.+ values in the prostate. Three parameters: a fractional signal segmentation constant, t.sub.F, a signal fat-fraction threshold, r.sub.F, and a population-based effective fat T.sub.1, T.sub.1f, were selected as 0.5, 90% and 320 ms, respectively, by comparing A.sub.RR-VFA with A.sub.REF. With these parameters, the interpolation error was within 3.5% in the prostate. On a single scanner, results showed various A.sub.RR-VFA in the prostate (with a range of 30%) and a significantly reduced range of T.sub.1 values after B.sub.1.sup.+ correction using RR-VFA. The multi-scanner study showed up to 14% intra-volunteer inter-scanner differences in rFA, and improved consistency of B.sub.1.sup.+ corrected T.sub.1 values across three MRI scanners. These results demonstrate not only the need for B.sub.1.sup.+ correction in the prostate, but also the effective characterization of the rFA in the prostate using RR-VFA without an additional acquisition for B.sub.1.sup.+ mapping.
(73) The manufacturer-provided sequence used as a reference for the optimization was chosen due to its universal availability on all of our MRI scanners. This B.sub.1.sup.+ mapping sequence carries an rFA bias dependent on the prescribed flip angle, mixing time, and tissue T.sub.1 assumption. As an example, in B.sub.1.sup.+ inhomogeneity mapping in the brain, a T.sub.1 bias of 300 ms with a mixing time of 28 ms yielded 0.6% bias in rFA for flip angles in the range of 40-140. This bias is quite small to begin with. Further, the fractional volume, , developed to compare A.sub.RR-VFA with A.sub.REF, was chosen to include the larger differences due to choices of T.sub.1f and r.sub.F in RR-VFA and exclude the smaller differences between the two methods that may have been due to the bias in the manufacturer-provided technique. Other B.sub.1.sup.+ mapping sequences can be used for similar comparisons with RR-VFA if their performance/bias characteristics can be accounted for.
(74) The population-based effective T.sub.1 within the fat tissue, T.sub.1f, was characterized as 320 ms across a population of healthy volunteers. Previous studies have reported fat T.sub.1 measurements of 367-382 ms in the pelvis and other anatomical regions at 3T. Although the inter-subject variability of T.sub.1f is small, these differences indicate that some heterogeneity in experimental set-up and analysis may cause a potential bias in the characterization of T.sub.1f. In our study, we found mean rFA variations of less than 2% in the suggested T.sub.1f range of 300-330 ms. Additionally, the improved quality of T.sub.1 maps in the pelvis and significantly reduced standard deviations of prostate and muscle T.sub.1 after B.sub.1.sup.+ correction suggest a good characterization of T.sub.1f.
(75) The other parameters in the optimization step were t.sub.F and r.sub.F, selected to facilitate accurate identification of fat reference regions surrounding the prostate. The optimized selectivity and sparsity of the fat tissue indicated a range of r.sub.F values between 80% and 95% and t.sub.F between 0.4 and 0.55. Within this range, we empirically selected r.sub.F=90% and t.sub.F=0.5 with the interpolation error <3.5%.The distribution of fat pixels is currently not a concern in the environment of the prostate but could be an important factor in effectively adapting RR-VFA to other anatomical areas. Future work may investigate an adaptive signal fat fraction threshold combined with a priori knowledge of the fat tissue distribution.
(76) In the single-scanner evaluation, RR-VFA showed variations (max-min) of up to 30% in the average A.sub.RR-VFA in the prostate among volunteers. The difference between average A.sub.REF and A.sub.RR-VFA was within 3%, suggesting that RR-VFA is comparable with the manufacturer-provided B.sub.1.sup.+ mapping protocol. The corresponding prostate T.sub.1non showed a variation of 1055 ms (range: 1560-2615 ms) across 10 volunteers, decreasing to 347 ms (range: 1812-2159 ms) after B.sub.1.sup.+ correction using RR-VFA. In addition, we evaluated T.sub.1 values in the obturator internus muscles adjoining the prostate to its left and right and showed improved consistency of the B.sub.1.sup.+ corrected T.sub.1 values (within 5 ms of each other). These results demonstrate the effectiveness of RR-VFA for B.sub.1.sup.+ mapping and indicate its potential in reducing T.sub.1 estimation errors.
(77) In the multi-scanner evaluation, RR-VFA showed differences of up to 14% in A.sub.RR-VFA within a volunteer scanned on three scanners. This rFA difference corresponded to an average CoV of 14.5% in T.sub.1non estimated from different scanners for the same individual volunteers that reduced to an average CoV of 5.1% in T.sub.1RR-VFA. The multi-scanner comparison thus demonstrates a decreased range of T.sub.1RR-VFA values (as shown in
(78) In conclusion, the RR-VFA technique was optimized for simultaneous mapping of B.sub.1.sup.+ and T.sub.1 in the prostate and performed evaluations in healthy volunteers within and across 3T MRI scanners. With the optimized parameters, relative flip angle characterized by RR-VFA showed differences of up to 30% across volunteers in the prostate on a single scanner, comparable to that from a manufacturer-provided B.sub.1.sup.+ mapping protocol without the need for an additional scan. Inter-scanner coefficient of variations of estimated T.sub.1 for the same subject reduced from 15% to 5% after RR-VFA B.sub.1.sup.+ correction. The application of RR-VFA B.sub.1.sup.+ correction has the potential to greatly improve T.sub.1 quantification consistency, resulting in improved quantitative DCE-MRI of the prostate.
(79) Embodiments of the present technology may be described herein with reference to flowchart illustrations of methods and systems according to embodiments of the technology, and/or procedures, algorithms, steps, operations, formulae, or other computational depictions, which may also be implemented as computer program products. In this regard, each block or step of a flowchart, and combinations of blocks (and/or steps) in a flowchart, as well as any procedure, algorithm, step, operation, formula, or computational depiction can be implemented by various means, such as hardware, firmware, and/or software including one or more computer program instructions embodied in computer-readable program code. As will be appreciated, any such computer program instructions may be executed by one or more computer processors, including without limitation a general purpose computer or special purpose computer, or other programmable processing apparatus to produce a machine, such that the computer program instructions which execute on the computer processor(s) or other programmable processing apparatus create means for implementing the function(s) specified.
(80) Accordingly, blocks of the flowcharts, and procedures, algorithms, steps, operations, formulae, or computational depictions described herein support combinations of means for performing the specified function(s), combinations of steps for performing the specified function(s), and computer program instructions, such as embodied in computer-readable program code logic means, for performing the specified function(s). It will also be understood that each block of the flowchart illustrations, as well as any procedures, algorithms, steps, operations, formulae, or computational depictions and combinations thereof described herein, can be implemented by special purpose hardware-based computer systems which perform the specified function(s) or step(s), or combinations of special purpose hardware and computer-readable program code.
(81) Furthermore, these computer program instructions, such as embodied in computer-readable program code, may also be stored in one or more computer-readable memory or memory devices that can direct a computer processor or other programmable processing apparatus to function in a particular manner, such that the instructions stored in the computer-readable memory or memory devices produce an article of manufacture including instruction means which implement the function specified in the block(s) of the flowchart(s). The computer program instructions may also be executed by a computer processor or other programmable processing apparatus to cause a series of operational steps to be performed on the computer processor or other programmable processing apparatus to produce a computer-implemented process such that the instructions which execute on the computer processor or other programmable processing apparatus provide steps for implementing the functions specified in the block(s) of the flowchart(s), procedure (s) algorithm(s), step(s), operation(s), formula(e), or computational depiction(s).
(82) It will further be appreciated that the terms programming or program executable as used herein refer to one or more instructions that can be executed by one or more computer processors to perform one or more functions as described herein. The instructions can be embodied in software, in firmware, or in a combination of software and firmware. The instructions can be stored local to the device in non-transitory media, or can be stored remotely such as on a server, or all or a portion of the instructions can be stored locally and remotely. Instructions stored remotely can be downloaded (pushed) to the device by user initiation, or automatically based on one or more factors.
(83) It will further be appreciated that as used herein, that the terms processor, hardware processor, computer processor, central processing unit (CPU), and computer are used synonymously to denote a device capable of executing the instructions and communicating with input/output interfaces and/or peripheral devices, and that the terms processor, hardware processor, computer processor, CPU, and computer are intended to encompass single or multiple devices, single core and multicore devices, and variations thereof.
(84) From the description herein, it will be appreciated that that the present disclosure encompasses multiple embodiments which include, but are not limited to, the following:
(85) 1. An apparatus for imaging a target tissue, comprising: (a) a processor; and (b) a non-transitory memory storing instructions executable by the processor; (c) wherein said instructions, when executed by the processor, perform steps comprising: (i) acquiring one or more images of the target tissue and surrounding target tissues; (ii) identifying and characterizing a reference tissue region within the one or more acquired images, the reference tissue region being adjacent or in proximity to the target tissue within a field of view of the one or more images, the reference tissue region being well-defined within the one or more images and having a consistent characteristic parameter that is known or readily estimated; (iii) calculating an unknown parameter within the reference region; (iv) interpolating the calculated unknown parameter of the reference region over the entire field of view of the one or more images; and (v) outputting image data of the one or more images, the image data comprising a parametric map of the target tissue.
(86) 2. The apparatus of any preceding embodiment, wherein the target tissue comprises a tissue having imaging characteristics that are not well-defined or having a consistent characteristic parameter that is known or readily estimated.
(87) 3. The apparatus of any preceding embodiment, wherein the reference tissue comprises a fat tissue in proximity to or at least partially surrounding the target tissue.
(88) 4. The apparatus of any preceding embodiment, wherein the target tissue comprises a prostate tissue having little or no fat tissue.
(89) 5. The apparatus of any preceding embodiment, wherein acquiring one or more images of the target tissue comprises performing quantitative dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) at 3T using three-dimensional RF-spoiled gradient echo images with variable flip angles (VFA) to generate the parametric map comprising T.sub.1 measurements.
(90) 6. The apparatus of any preceding embodiment: wherein T.sub.1 measurements are susceptible to B.sub.1.sup.+ field inhomogeneity comprising errors due to spatial variations in flip angle caused by transmit radiofrequency (RF) from the quantitative DCE-MRI; and wherein outputting image data comprises simultaneously mapping T.sub.1 and B.sub.1.sup.+ field inhomogeneity values associated with the target tissue.
(91) 7. The apparatus of any preceding embodiment: wherein calculating the unknown parameter in the reference region comprises estimating B.sub.1.sup.+ field inhomogeneity in the fat tissue; and wherein interpolating the calculated unknown parameter of the reference region comprises interpolating the estimating B.sub.1.sup.+ inhomogeneity over at least a portion of the FOV of the one or more images, the portion comprising the target tissue.
(92) 8. The apparatus of any preceding embodiment, wherein the consistent characteristic parameter comprises an effective fat T.sub.1 value associated with the reference region; and wherein the unknown parameter of the reference region comprises an rFA value associated with the reference region.
(93) 9. The apparatus of any preceding embodiment, wherein identifying and characterizing a reference tissue region comprises: applying a combination of a user-selectable parameter for fat signal segmentation and a signal fat-fraction threshold; and building a binary fat tissue mask of the reference tissue region.
(94) 10. The apparatus of any preceding embodiment, wherein Dixon-separated fat and water images are used to build the binary fat mask.
(95) 11. The apparatus of any preceding embodiment, wherein the binary fat mask is used to characterize an rFA value associated with the reference region; and wherein interpolating the calculated unknown parameter of the reference region comprises interpolating the rFA value at least a portion of the FOV of the one or more images, the portion comprising the target tissue.
(96) 12. The apparatus of any preceding embodiment, wherein the rFA value comprises B.sub.1.sup.+ field inhomogeneity.
(97) 13. The apparatus of any preceding embodiment, wherein interpolating the calculated unknown parameter of the reference region comprises computing a fractional volume of outliers comprising a combination of user-selectable parameter for fat signal segmentation, the signal fat-fraction threshold, and effective fat T.sub.1 values.
(98) 14. A method for imaging a target tissue, comprising: acquiring one or more images of the target tissue and surrounding target tissues; identifying and characterizing a reference tissue region within the one or more acquired images, the reference tissue region being adjacent or in proximity to the target tissue within a field of view of the one or more images, the reference tissue region being well-defined within the one or more images and having a consistent characteristic parameter that is known or readily estimated; calculating an unknown parameter within the reference region; interpolating the calculated unknown parameter of the reference region over the entire field of view of the one or more images; and outputting image data of the one or more images, the image data comprising a parametric map of the target tissue.
(99) 15. The method of any preceding embodiment, wherein the target tissue comprises a tissue having imaging characteristics that are not well-defined or having a consistent characteristic parameter that is known or readily estimated.
(100) 16. The method of any preceding embodiment, wherein the reference tissue comprises a fat tissue in proximity to or at least partially surrounding the target tissue.
(101) 17. The method of any preceding embodiment, wherein the target tissue comprises a prostate tissue having little or no fat tissue.
(102) 18. The method of any preceding embodiment, wherein acquiring one or more images of the target tissue comprises performing quantitative dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) at 3T using three-dimensional RF-spoiled gradient echo images with variable flip angles (VFA) to generate the parametric map comprising T.sub.1 measurements.
(103) 19. The method of any preceding embodiment, wherein T.sub.1 measurements are susceptible to B.sub.1.sup.+ field inhomogeneity comprising errors due to spatial variations in flip angle caused by transmit radiofrequency (RF) from the quantitative DCE-MRI; and wherein outputting image data comprises simultaneously mapping T.sub.1 and B.sub.1.sup.+ field inhomogeneity values associated with the target tissue.
(104) 20. The method of any preceding embodiment, wherein calculating the unknown parameter in the reference region comprises estimating B.sub.1.sup.+ field inhomogeneity in the fat tissue; and wherein interpolating the calculated unknown parameter of the reference region comprises interpolating the estimating B.sub.1.sup.+ inhomogeneity over at least a portion of the FOV of the one or more images, the portion comprising the target tissue.
(105) 21. The method of any preceding embodiment, wherein the consistent characteristic parameter comprises an effective fat T.sub.1 value associated with the reference region; and wherein the unknown parameter of the reference region comprises an rFA value associated with the reference region.
(106) 22. The method of any preceding embodiment, wherein identifying and characterizing a reference tissue region comprises: applying a combination of a user-selectable parameter for fat signal segmentation and a signal fat-fraction threshold; and building a binary fat tissue mask of the reference tissue region.
(107) 23. The method of any preceding embodiment, wherein Dixon-separated fat and water images are used to build the binary fat mask.
(108) 24. The method of any preceding embodiment, wherein the binary fat mask is used to characterize an rFA value associated with the reference region; and wherein interpolating the calculated unknown parameter of the reference region comprises interpolating the rFA value at least a portion of the FOV of the one or more images, the portion comprising the target tissue.
(109) 25. The method of any preceding embodiment, wherein the rFA value comprises B.sub.1.sup.+ field inhomogeneity.
(110) 26. The method of any preceding embodiment, wherein interpolating the calculated unknown parameter of the reference region comprises computing a fractional volume of outliers comprising a combination of user-selectable parameter for fat signal segmentation, the signal fat-fraction threshold and effective fat T.sub.1 values.
(111) 27. A method for magnetic resonance tissue imaging, the method comprising: (a) obtaining T.sub.1 values of a reference region of a tissue at approximately 3T or higher; (b) mapping B.sub.1.sup.+ values of the reference region of tissue; (c) measuring T.sub.1 and B.sub.1.sup.+ maps of a non-reference target region of a tissue simultaneously with Region Variable Flip Angle (RR-VFA) using; and (d) using measured T.sub.1 and B.sub.1.sup.+ values with dynamic contrast-enhanced MRI (DCE-MRI) or Multi-parametric MRI (mp-MRI) to form an image of the target region of tissue.
(112) 28. The method of any preceding embodiment, further comprising: identifying reference tissue regions for B.sub.1.sup.+ mapping with a scheme selected from the group consisting of a two-point Dixon scheme, a manual segmentation scheme, or semi-manual segmentation scheme.
(113) 29. The method of any preceding embodiment, further comprising: acquiring a time series of T.sub.1-weighted MRI scans of a target tissue before and after injection of a contrast agent.
(114) 30. A method for magnetic resonance imaging of prostate tissue, the method comprising: (a) measuring T.sub.1 relaxation times of a reference region of a fat tissue surrounding the prostate of a subject with magnetic resonance imaging; (b) determining effective fat T.sub.1 and relative flip angle (rFA) values from an MRI signal from the fat tissue; (c) simultaneously measuring T.sub.1 and B.sub.1.sup.+ maps using reference region variable flip angle (RR-VFA) imaging; (d) acquiring magnetic resonance scans of the prostate with a standard clinical protocol of a three-dimensional gradient echo with several low flip angles; and (e) forming an image from magnetic resonance imaging data.
(115) 31. An apparatus for magnetic resonance imaging, comprising: (a) a magnetic resonance scanner; (b) a computer processor operably coupled to the scanner; and (c) a non-transitory computer-readable memory storing instructions executable by the computer processor; (d) wherein said instructions, when executed by the computer processor, perform steps comprising: (i) obtaining T.sub.1 values of a reference region of a tissue at approximately 3T or higher; (ii) mapping B.sub.1.sup.+ values of the reference region of tissue; and (iii) measuring T.sub.1 and B.sub.1.sup.+ maps of a non-reference target region of a tissue simultaneously with Region Variable Flip Angle (RR-VFA) using; and (iv) using measured T.sub.1 and B.sub.1.sup.+ values with dynamic contrast-enhanced MRI (DCE-MRI) or Multi-parametric MRI (mp-MRI) to form an image of the target region of tissue.
(116) 32. A computer implemented method for magnetic resonance imaging, the method comprising: (a) obtaining T.sub.1 values of a reference region of a tissue at approximately 3T or higher with an MRI imager; (b) mapping B.sub.1.sup.+ values of the reference region of tissue; (c) measuring T.sub.1 and B.sub.1.sup.+ maps of a non-reference target region of a tissue simultaneously with Region Variable Flip Angle (RR-VFA) using; and (d) using measured T.sub.1 and B.sub.1.sup.+ values with dynamic contrast-enhanced MRI (DCE-MRI) or Multi-parametric MRI (mp-MRI) to form an image of the target region of tissue; (e) wherein said method is performed by a computer processor executing instructions stored on a non-transitory computer-readable medium.
(117) Although the description herein contains many details, these should not be construed as limiting the scope of the disclosure but as merely providing illustrations of some of the presently preferred embodiments. Therefore, it will be appreciated that the scope of the disclosure fully encompasses other embodiments which may become obvious to those skilled in the art.
(118) In the claims, reference to an element in the singular is not intended to mean one and only one unless explicitly so stated, but rather one or more. All structural, chemical, and functional equivalents to the elements of the disclosed embodiments that are known to those of ordinary skill in the art are expressly incorporated herein by reference and are intended to be encompassed by the present claims. Furthermore, no element, component, or method step in the present disclosure is intended to be dedicated to the public regardless of whether the element, component, or method step is explicitly recited in the claims. No claim element herein is to be construed as a means plus function element unless the element is expressly recited using the phrase means for. No claim element herein is to be construed as a step plus function element unless the element is expressly recited using the phrase step for.
(119) TABLE-US-00001 TABLE 1 A.sub.RR-VFA (%) A.sub.REF (%) T.sub.1non (ms) T.sub.1RR-VFA (ms) T.sub.1REF (ms) Region (Range) (Range) (Range) (Range) (Range) Prostate 102.6 8.5 105.4 5.5 2112 333 1998 113 1900 190 (90.7-121.4) (96.9-115.7) (1560-2615) (1812-2159) (1480-2107) Muscle (L) 108.9 6.69 109.4 5.6 1722 229 1443 70 1443 123 (98.5-121.2) (97.4-115.3) (1282-2068) (1325-1563) (1199-1587) Muscle (R) 102.2 8.75 104.9 6.8 1557 275 1440 67 1371 134 (86.5-118.0) (96.6-115.7) (1015-1934) (1353-1550) (1065-1503)
(120) TABLE-US-00002 TABLE 2A Scanner 1 Scanner 2 Scanner 3 A.sub.RR-VFA(%) A.sub.RR-VFA (%) A.sub.RR-VFA(%) Mean SD/ Mean SD/ Mean SD/ Parameter (min-max) (min-max) (min-max) Volunteer A 95.6 4.5 86.9 2.22 96.6 1.75 (88-105) (81-91) (93-100) Volunteer B 99.4 2.31 96.4 5.39 100.5 1.65 (95-105) (86-108) (98-104) Volunteer C 101.2 1.54 87.5 2.28 90.3 1.29 (96-105) (82-92) (86-93) Volunteer D 96.9 1.76 91.0 2.87 103.0 2.15 (94-101) (85-97) (95-106) Mean SD 98.3 2.5 90.5 4.4 97.6 5.5
(121) TABLE-US-00003 TABLE 2B A.sub.RR-VFA(%) T.sub.1non (ms) T.sub.1RR-VFA (ms) (min-max)/ (min-max)/ CoV % (min-max)/ Parameter Range Range (T.sub.1non) Range Volunteer A 86.9- 1530- 8.23 1902- 96.6/9.7 1772/242 2029/127 Volunteer B 96.4- 1844- 6.25 1995- 100.5/4.1 2084/240 2063/68 Volunteer C 87.5- 1260- 27.75 1646- 101.2/13.7 2119/859 2072/426 Volunteer D 91.0- 1469- 15.96 1779- 103.0/12.0 2028/559 1910/131